Sea Purity Investment Portfolio

Sea Purity Portfolio Chart

Software Vertical

Disruptive Technology Products

Socially Responsive Investing

Pharma / Biotech

Medtech / Device

Consumer

Alternative Funds

Real Estate

Significant Wins and Exits

Raises $40M on a $300M valuation – Read the entire article @ Techcrunch

Company announces that its PRV-031 therapeutic helps delay the onset of Type 1 Diabetes by up to 2 years for High Risk individuals. The stock is up over 6X our ownership basis in the Pre-IPO round.

KKR purchases minority stake in Arbor Pharmaceuticals at a valuation of over $1 Billion.

Novartis purchases Encore Vision for almost $500 million.

 

 

Acorns raised $105 million in a Series E round at an $860 million valuation. Investors include Comcast venture, NBCUniversal, Bain Capital and Blackrock.

 

 

Purchased by Great Hill Partners for $40.50 per share.

 

 

Former management team of AbbVie subsidiary purchases 17% interest and stock trades into the $20’s.

 


Pre-IPO investment which netted a 500% return.

Location

San Clemente, CA, United States

Phone

949-391-0980

Email

matt.hayden@seapurity.us